Skip to main content

Work in progress

Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.


Open consultations

We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.

  • We don't have any consultations open at the moment but please check back here regularly for updates.

Back to top


Medicines optimisation projects

Title: All Wales Medicine Management Guidelines for Integrated Community Based Services

Status: Consultation completed

Remit: This guideline is focused on community care and designed to address the unique needs and challenges faced by registered service providers ensuring consistent medicine advice in diverse care settings. Specifically designed to guide local policy development, this guideline aims to establish a unified and integrated policy across health and social care, providing comprehensive guidance for medicine optimisation.

Estimated publication date: September-November 2025

Title: All Wales Shared Care Framework

Status: Consultation completed

Remit: To review and refine the current principles for the use of shared care within NHS Wales and to develop an All Wales framework that sets out the principles of shared care and supports health boards and prescribers in the appropriate use of shared care.

Estimated publication date: June 2025-August 2025

Title: All Wales Common Ailments Service Formulary - Monograph for back pain

Status: Consultation completed

Remit: The Common Ailments Service aims to improve patient access to consistent, evidence-based advice for the management of common ailments.

The Welsh Medicines Advice Service (WMAS), in collaboration with the Community Pharmacy Clinical Advisory Group, have updated the back pain monograph to reflect the NICE Clinical Knowledge Summary update of October 2024, which incorporates the NICE guidance [NG234] on Spinal metastases and metastatic spinal cord compression.

Estimated publication date: June 2025-August 2025

Back to top


Medicines under consideration by AWMSG Scrutiny Panel

Medicine name: bimekizumab (Bimzelx®)

Reference number: 4510

Indication: Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy

Licence status: Licensed

AWMSG Scrutiny Panel meeting date: 19/06/2025

Medicine name: venetoclax (Venclyxto®) plus azacitidine

Reference number: 6860

Indication: Off-label treatment of relapsed / refractory (R/R) acute myeloid leukaemia (AML) following at least one line of intensive chemotherapy – this includes scenarios of molecular relapse, and relapse following allogeneic haematopoietic stem cell transplant [HSCT]) in situations where:

  • it is deemed not appropriate to offer intensive ‘salvage chemotherapy’ by the treating physician / multi-disciplinary team
  • the patient has not previously demonstrated refractoriness or intolerance to venetoclax-based therapy

Licence status: Off-label for the indication under consideration

AWMSG Scrutiny Panel meeting date: 19/06/2025

Back to top


Licensed medicines assessments

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Back to top


Off-label (One Wales) medicines assessments

Medicine name: infliximab

Reference number: OW31

Indication: For the off-label treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 myocarditis that has not responded to first line immunosuppression with corticosteroids.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 01/07/2025

OWMAG date: 11/08/2025

AWMSG date: 10/09/2025

Back to top


Policies, strategies and other publications

 

Title: AWMSG annual report 2024-2025

Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2023 and March 2024.

Estimated publication date: September 2025

View previous AWMSG annual reports

Title: IPFR annual report 2024-2025

Summary: Review of Individual Patient Funding Request activity in Wales between April 2023 and March 2024. 

Estimated publication date: September 2025

View previous IPFR annual reports

Back to top

Follow AWTTC: